The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial
View Full Paper
Ask AI
Bookmark
Share
Key result
Pegylated liposomal doxorubicin demonstrated an overall clinical benefit rate of 24% in women with metastatic breast cancer previously treated with conventional anthracyclines.
Why the study?
Does pegylated liposomal doxorubicin provide clinical benefit in women with metastatic breast cancer previously treated with anthracyclines?
Structured PICO
Does pegylated liposomal doxorubicin provide clinical benefit in women with metastatic breast cancer previously treated with anthracyclines?
P
Population
79 women with metastatic breast cancer previously treated with anthracyclines, with a median age of 58 years, followed for a median of 30 months.
I
Intervention
Pegylated liposomal doxorubicin (PLD) 50 mg/m2 every 4 weeks
O
Outcome
Clinical benefit rate (objective response + stable disease >= 24 weeks)surrogate
Pegylated liposomal doxorubicin provides a modest but evident clinical benefit with a favorable cardiac safety profile in patients with metastatic breast cancer previously treated with anthracyclines.
Limitations
- Single-arm study design without a control group
- Small sample size
- Analysis was retrospectively restricted to a subgroup of 79 patients out of 100 enrolled to create a more homogeneous population
- Limitations to cross-study comparisons
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
May support use in anthracycline-pretreated metastatic breast cancer; leaves open need for randomized confirmation.
Cite This Study
Bischoff et al. (2006) studied Metastatic breast cancer (n=79). Pegylated liposomal doxorubicin was evaluated on Clinical benefit rate (objective response + stable disease ≥6 months duration) (95% CI 14.6-33.4). Pegylated liposomal doxorubicin demonstrated an overall clinical benefit rate of 24% in women with metastatic breast cancer previously treated with conventional anthracyclines.
View Full Paper
Ask AI
Bookmark
Share